Avidity Biosciences, Inc.

Wishing a joyful and prosperous Year of the Snake to all those celebrating #LunarNewYear.

At the American Strategic Portfolio Management in Life Sciences – West Coast conference, hosted by Why Summits, Avidity team members Qing (Ching) Chang, M.D., Ph.D., Ernest Chow, and Sarah Hudson, PhD, PMP® will speak to their experience and expertise in portfolio strategy. This event gathers leaders across pharma, biotech, medical devices, and diagnostics to explore how strategic portfolio management drives innovation and efficiency in a rapidly evolving industry. We're excited to contribute to the conversation and share how Avidity’s approach fosters innovation in life sciences. See the agenda: https://lnkd.in/ed32-HeN

#PRKAG2 syndrome is a rare, inherited and progressive cardiac caused by a mutation on the PRKAG2 gene that results in increased AMP-activated protein kinase (AMPK) activity. At Avidity, we are applying the versatility of our AOC™ platform to target the underlying causes of genetic #heartdiseases within precision #cardiology. Building on our advancements in neuromuscular disorders, we’re now expanding our AOC platform to potentially address rare genetic cardiac conditions like PRKAG2 syndrome. Learn more about our lead precision cardiology candidates and the latest innovations in our broader AOC platform in our recent volume: https://lnkd.in/eZ2q7ukX

Our Vice President of Biology, Hanhua Huang, PhD, will present at the RNAi-Based Therapeutics Summit on January 30 where he will discuss how we have utilized our proprietary Antibody Oligonucleotide Conjugate™ (AOC) platform to advance clinical programs for rare neuromuscular diseases and in precision cardiology. Learn more about our AOC platform and pipeline: https://lnkd.in/gWTKzDuU

Wrapping up a successful #JPMWeek, we are more energized than ever by the momentum driving Avidity’s mission to profoundly impact the lives of patients. #JPM2025 highlighted the exponential growth opportunities ahead as we prepare for a transformative year. As part of this forward momentum, Eric Mosbrooker is expanding his role to Chief Commercial Officer. Eric has been a driving force behind Avidity’s strategic vision, playing a key role in expanding our pipeline and laying the groundwork for future success. In his new role as CCO, Eric will be focused on strengthening our commercial strategy, building a global infrastructure to support our growing footprint, and accelerating the delivery of our AOCs to patients. His leadership will be integral as we enter this exciting next chapter, turning our vision into tangible, meaningful impact for those who need it most. Learn more in our press release: https://lnkd.in/ejebVCsE

Today, we honor Dr. Martin Luther King Jr.'s legacy and his vision for equity, justice, and acceptance. As we reflect on his powerful impact, we reaffirm our commitment to advancing his vision through our #BeAVID values and fostering inclusion, respect, and equality for all. #MLKDay

If you are interested in joining our #BeAVID team – agile, visionary, integrated, and diverse - stop by our careers page to check out our open positions. We are looking for exceptional people to become part of our fun, agile, dynamic, and innovative team as we work to bring much needed therapies to people living with serious rare diseases. Explore our current opportunities: https://lnkd.in/dWCgkwVY

We are excited to announce the appointment of Kat Lange as Chief Business Officer. With over a decade of experience in biotechnology investment banking, Kat has a remarkable track record in capital raising, strategic partnerships, and driving growth in the biotech industry. As we continue to advance a new class of targeted RNA therapeutics, Kat's expertise will be instrumental in strengthening our business strategy and supporting our mission to profoundly improve the lives of patients. For details, see our press release: https://lnkd.in/ejebVCsE

Tomorrow during a presentation at the J.P. Morgan Healthcare Conference in San Francisco, our President and CEO, Sarah Boyce, will share Avidity’s vision for the future and our commitment to transforming the lives of people living with rare diseases. Sarah will highlight how we are turning that vision into reality — advancing our AOC platform, progressing clinical programs for rare neuromuscular diseases, and developing precision #cardiology therapies for rare genetic cardiomyopathies. She will also discuss our journey toward becoming a global, commercial organization and delivering innovative treatments to patients worldwide. We look forward to joining industry leaders at #JPM2025 to discuss our role in shaping the future of medicine and driving meaningful impact for patients.

In the latest episode of Life Science Cares, Inc.'s “Moving Forward, Giving Back” podcast, our President & CEO, Sarah Boyce, joins host Jeff Marrazzo and fellow #lifescience leaders, including Robert Blum and Ron Cooper, to discuss #LifeScienceShares — a pledge program that empowers companies and executives to give back to their local communities. Sarah highlights Avidity’s commitment to addressing critical needs in San Diego, from providing basic necessities and improving access to education to creating economic opportunities. She discusses our recent grant to Life Science Cares, our partnership with Monarch School to inspire students, and our commitment to cultivating the next generation of leaders through Project Onramp. As we gear up for a busy #JPMWeek, tune in to learn more about our partnership with Life Science Cares and how we’re making a meaningful difference in the San Diego community: https://lnkd.in/eR_jWb_f